Articles
- Facial feminization surgery
- Dopamine agonists
- Sex reassignment surgery
- Imaging of the dopaminergic system in differential diagnosis of dementia.
- Dynamics of dopamine and norepinephrine contents in the dorsal hippocampus of rats during immunization with dopamine conjugate.
- Lobelia chinensis
- Selegiline-wikipedia spam
- What is the most important information I should know about selegiline?
- What is Selegiline?
- Selegiline patch doesn't alter sexual function
- Important Warning
- Inexpensive Drug Effective in Early Parkinson's
- Selegiline Treatment Report
- Safety of nicotine: the smoke causes the harm
- USPSYCH: Depression Remission Rates Remain Low, But There's Hope
- Aging Cat's Caterwauls Could Be a Sign of Dementia
Imaging of the dopaminergic system in differential diagnosis of dementia.
Tatsch K.
Department of Nuclear Medicine, University of Munich Hospital – Campus Großhadern, Marchioninistr. 15, 81377, Munich, Germany, Klaus.Tatsch@med.uni-muenchen.de.
Neurodegenerative dementia is an increasingly common disorder with Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) accounting for most cases. Due to the overlap in clinical symptoms, their differential diagnosis may be challenging. As clinical classification is not completely satisfying, there is a need to improve the diagnostic accuracy by complementary methods such as functional single-photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging. The latter may be helpful to address one distinct biological difference between DLB and AD, the severe nigrostriatal degeneration which occurs in DLB, but not to any significant extent in AD. Based on this principle, autoradiographic studies targeting presynaptic dopaminergic functions have consistently demonstrated the ability to distinguish DLB from AD in postmortem series. At the same time, several single-site and one multicentre study have independently confirmed-no matter what technique was used (SPECT or PET) and which presynaptic function was addressed (dopamine turnover, dopamine transporter, vesicular monoamine transporter)-significantly compromised scan results in DLB subjects, whereas AD patients maintained almost normal findings. Even more important, in vivo findings of presynaptic dopaminergic imaging correlated well with neuropathological findings at autopsy, suggesting a remarkable sensitivity of 88% and a specificity of 100% for the imaging procedure to distinguish between DLB and AD. Taken together, imaging of presynaptic dopaminergic terminal functions with SPECT and PET has currently the greatest evidence base to support its use, and therefore, may be highly recommended to help in the discrimination between DLB and AD. Compared to presynaptic functions, corresponding data targeting postsynaptic dopamine receptors are comparatively rare, less conclusive and suggest a very limited role for this purpose. This review discusses the findings of studies specifically dealing with imaging of the dopaminergic system in the differential diagnosis of dementia.